AbbVie Q2 misses estimates; stock down over 4%

24 July 2015
abbvie-logo-big

US drugmaker AbbVie (NYSE: ABBV) on Friday posted second quarter results that fell short of estimates on slower than expected sales growth for its top-selling drug Humira.

The company posted profit of $1.37 billion, up over 13% from a year ago. Earnings per share rose to 83 cents from 68 cents year on year. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.06 per share.

Excluding special items, earnings per share were up at $1.08 against 82 cents a year earlier. Revenue grew 11% to $5.48 billion. The US-based firm said sales were impacted by 8.3% from unfavorable foreign currency exchange rates. This was also shy of Wall Street expectations, with five analysts surveyed by Zacks expecting $5.6 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical